September 22, 2016 14:00 ET
OTTAWA, ONTARIO--(Marketwired - Sept. 22, 2016) - Patented Medicine Prices Review Board
The Patented Medicine Prices Review Board (the Board) will hold a public hearing with respect to allegations that Galderma Canada Inc. failed to provide Board Staff with the pricing and sales information required under section 80 of the Patent Act and sections 3 and 4 of the Patented Medicines Regulations. This proceeding relates to the medicines sold under the brand names Differin, Differin XP, TactuPump, and TactuPump Forte, which are generally indicated for the treatment of acne.
The public hearing is scheduled to take place from 10:00 a.m. to 4:00 p.m. (EST) from September 26 to September 27, 2016 at the following location:
The purpose of the hearing is to receive evidence and argument of Board Staff and Galderma Canada Inc. regarding allegations that Galderma Canada Inc. is in breach of its reporting requirements.
Notice of Hearing
Notice of Application - Failure to File
Patent Act (Justice Canada)
Patented Medicines Regulations (Justice Canada)
Status of Ongoing Proceedings (Patented Medicine Prices Review Board)
Follow us on Twitter: @PMPRB_CEPMB
Sofie McCoy-AstellManager, CommunicationsPatented Medicine Prices Review Board613-960-9728Sofie.McCoy-Astell@pmprb-cepmb.gc.caTTY (telecommunications device for the hearing impaired)613-957-4373
See all RSS Newsfeeds